HBRI’s Office of Business Development manages the intellectual property of the Institute.
At the HBRI Office of Business Development, the mission is to enable researchers at HBRI to realize the commercial potential of their ideas. The goal is to develop and support relationships with industry partners who can help turn scientific progress in the lab into tangible products for the benefit of patients and society at large, and to help support further Institute research.
HBRI’s Office of Business Development maintains close relationships with HBRI faculty and scientific staff. The Office of Business Development evaluates inventions created by HBRI researchers for their commercial potential. The Office of Business Development engages with potential industry partners to help develop the technologies that can result in licensing intellectual property or collaboration with a partner.
HBRI’s Office of Business Development manages the Institute’s patent portfolio and oversees material transfer, confidential disclosure and inter-institutional agreements. Since HBRI’s founding, technology management has resulted in numerous patents and generated license agreements with strategic partners.
Technology and Agreements developed at the Institute falls into these broad categories:
Therapeutics and diagnostics
Technologies that are primarily useful to develop therapeutics and diagnostics are often licensed exclusively.
Corporate sponsored research agreements
Corporate Sponsored Research Agreements (CSRA) which support a specific research project in the lab of one of our faculty and include an option to license any jointly developed technology that may be generated as a result of the collaboration along with underlying Institute technology.
Research tools are licensed non-exclusively for research purposes only. These include small molecules, antibodies, plasmids, genes, and biomarkers to name a few.
Current Technologies Available for Development:
Metabolically Stable Agents for Alcohol and Drug Abuse
Compounds as Modulators of Smoking and Lung Cancer
Metabolically Stable Analgesics and Pain Medications
Modulators of CNS Neurotransmitters
Diagnostic Methods and Genetic Markers for Alzheimer’s Disease
Biomarkers for Organophosphate Exposure
Small Molecule Immunostimulants for Alzheimer’s Disease
Compounds to Decrease Nicotine Self-Administration
Oximes for Cholinesterase Reactivation
Compounds and Matrices for Use in Bone Growth and Repair
Compounds for Stem Cell Differentiation
Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells